Cannabis Could Help Reduce Opioid Use in Patients with Chronic Pain
Drug Topics
DECEMBER 2, 2024
Most patients with reduced opioid prescriptions during cannabis use had chronic musculoskeletal pain.
Mon.Dec 02, 2024
212 
FDA Approves Ustekinumab-kfce as Biosimilar to Ustekinumab
Pharmacy Times
DECEMBER 2, 2024
The biosimilar is approved for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Influenza Vaccine Least Effective for Children Facing Secondary Infection
Drug Topics
DECEMBER 2, 2024
Researchers addressed vaccine effectiveness for individuals with direct household contacts that reported influenza.
Legislators urge DOJ to investigate PBMs for potential role in opioid epidemic
Fierce Healthcare
DECEMBER 2, 2024
A group of legislators is calling on the Department of Justice to dig into whether pharmacy benefit managers played a role in the opioid epidemic. | A group of legislators is calling on the Department of Justice to dig into whether pharmacy benefit managers played a role in the opioid epidemic.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
RFK Jr. could 'cost lives in this country' if he pursues changes to US vaccine policy, Gottlieb says
Fierce Pharma
DECEMBER 2, 2024
Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.
M&A or affiliation improved rural hospitals' margins, reduced risk of closure: report
Fierce Healthcare
DECEMBER 2, 2024
Nearly half of rural hospitals moved out of the high-risk category after a merger, acquisition or affiliation with a larger system, a new analysis has found. | The analysis, conducted by healthcare consulting firm Dobson DaVanzo, found that among 110 rural hospitals that closed between 2011 and 2021, more than half were standalone hospitals without support from larger systems.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Bird flu theories, the worst-rated restaurants, and not your grandfather’s radiation therapy
STAT
DECEMBER 2, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! I hope you had a lovely holiday weekend and feel rested and ready for the last sprint of 2024.
Looming PREP Act Expiration Could Impact Health Care Access for Rural Patients
Pharmacy Times
DECEMBER 2, 2024
The Act is set to end at the end of 2024, which will affect pharmacists’ abilities to administer COVID-19 tests, vaccines, and treatment that are distributed by the federal government.
Novartis pays $1bn upfront for Huntington's drug from PTC
pharmaphorum
DECEMBER 2, 2024
Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront
Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events
Pharmacy Times
DECEMBER 2, 2024
AI-enabled remote cardiac telemetry can help manage stress’s effects on high-risk populations.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Orexo exits depression DTx alliance with GAIA
pharmaphorum
DECEMBER 2, 2024
Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
Study Finds Associations Between Memory Difficulties and History of Asthma in Children
Pharmacy Times
DECEMBER 2, 2024
Asthma onset earlier in childhood may be linked to more severe difficulties that could extend to executive function abilities.
BMS files legal challenge to HHS' 340B rebate decision
pharmaphorum
DECEMBER 2, 2024
Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
CBT, Rehabilitation May Improve Symptoms of Long COVID
Drug Topics
DECEMBER 2, 2024
A recent study showed that cognitive behavioral therapy could help reduce fatigue and improve concentration with moderate certainty.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Abingworth 'will launch $1.5bn fund for co-developed drugs'
pharmaphorum
DECEMBER 2, 2024
Abingworth 'will launch $1.5bn fund for co-developed drugs' Phil.
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
PharmaVoice
DECEMBER 2, 2024
Intrinsic Medicines is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
Part Two: Navigating the complexities of global market access for rare and complex conditions
pharmaphorum
DECEMBER 2, 2024
Part Two: Understand the challenges faced by drug manufacturers when navigating the complexities of global market access for rare and complex conditions. Learn how to overcome these obstacles successfully.
Zerlasiran Shows Significant Lipoprotein(a) Reduction in Phase 2 Trial
Pharmacy Times
DECEMBER 2, 2024
Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Orexo exits depression DTx alliance with GAIA
pharmaphorum
DECEMBER 2, 2024
Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
Fierce Healthcare Fundraising Tracker—Sirona Medical picks up $42M; Alloy banks $16M for menopause care
Fierce Healthcare
DECEMBER 2, 2024
At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health industries. | Beta Bionics landed $60 million for diabetes management solutions, Medicaid startup Diverge Health picked up $52 million backed by GV and TailorMed secured $40 million for its patient financial assistance platform. Check out other recent funding rounds.
Alligator eyes sweeping job cuts and pares down its pipeline
pharmaphorum
DECEMBER 2, 2024
Alligator eyes sweeping job cuts and pares down its pipeline Phil.
Sanofi charts biggest China investment to date with plans for €1B insulin 'manufacturing base' in Beijing
Fierce Pharma
DECEMBER 2, 2024
Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. | Sanofi is laying out roughly 1 billion euros ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone. The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to beef up local end-to-end insulin production.
Patients With Anemia and Myelofibrosis Have Worse Survival Outcomes When Treated With Ruxolitinib
Pharmacy Times
DECEMBER 2, 2024
Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.
ICHRA-focused StretchDollar raises $6M with help from Oscar Health
Fierce Healthcare
DECEMBER 2, 2024
Health benefits startup StretchDollar has raised $6 million from its latest seed funding rounds to improve its self-service platform, the company announced today. | Health benefits startup StretchDollar has raised $6 million, with help from Oscar Health, as the two companies put their weight behind ICHRAs.
How BuSpar could help you sleep
The Checkup by Singlecare
DECEMBER 2, 2024
You’re staring at the ceiling in the middle of the night, counting sheep, but instead of lulling you into a peaceful slumber, they won’t stop jumping around in your mind. If you regularly struggle with sleep issues, finding the right solution can feel like finding a needle in a haystack. Pharmaceutical options such as benzodiazepines like diazepam and antidepressants like trazodone are sometimes used off-label to treat insomnia in adults.
Veradigm launches AI scribe for small and independent practices
Fierce Healthcare
DECEMBER 2, 2024
Veradigm has launched an ambient AI scribe powered by AvodahMed to allow practitioners to save time generating patient encounter notes and reduce provider burnout. | AvodahMed and Veradigm worked closely to integrate the scribe into Veradigm's EHR solutions to maximize the time savings of the technology.
Photoacoustic Breast Imaging Can Reduce Skin Tone Biases While Detecting Cancer Early
Pharmacy Times
DECEMBER 2, 2024
When different skin tones are considered in imaging systems, women will receive more equitable screening and care.
Pharma Horizons: Sustainability
European Pharmaceutical Review
DECEMBER 2, 2024
This report delves into the latest developments in sustainability impacting the pharmaceutical sector today. Inside, articles explore current key topics including regulation, manufacturing, green chemistry, digitalisation and clinical trials. Stay up to date with the latest developments in sustainability including articles on: The key regulatory frameworks impacting the pharmaceutical industry and the challenges and opportunities around their implementation How digitalisation can transform and
Best Practices for Standardizing Step-Up Dosing
Pharmacy Times
DECEMBER 2, 2024
Panelists discuss how specific recommended dosing schedules exist for step-up medication administration, and protocols should incorporate flexibility for individualized dose adjustments based on patient response, tolerability, and clinical factors while maintaining systematic documentation of any deviations from standard escalation timelines.
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports
Fierce Pharma
DECEMBER 2, 2024
The FDA is investigating reports of patients develo | The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer.
PrimeRx Expands Leadership Team, Naming David Kirkus, Pharm.D., as VP of PrimeRx MARKET
Pharmacy Times
DECEMBER 2, 2024
Key Appointment Focused on Driving Innovation in Pharmacy Inventory Management
How much is Combivent Respimat without insurance?
The Checkup by Singlecare
DECEMBER 2, 2024
Combivent Respimat is a combination of the drugs albuterol and ipratropium, commonly prescribed to treat chronic obstructive pulmonary disease (COPD)—a group of pulmonary medical conditions (like chronic bronchitis) that make breathing difficult. As a bronchodilator, Combivent Respimat comes in an inhaler and can help open constricted airways. It can sometimes be expensive, and although there are no over-the-counter or generic versions, there are still some potentially cheaper alternatives.
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Pharmacy Times
DECEMBER 2, 2024
It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Let's personalize your content